ABSTRACT
OBJECTIVE: To observe the clinical effect of Guilu Erxian Glue Cataplasm (GEGC) on carcinoma of the large intestine patients with myelosuppression after chemotherapy, and further to confirm its efficiency and safety. METHODS: Totally 60 patients with carcinoma of the large intestine were randomly assigned to two groups. Meanwhile, they all accepted FOLFIRI chemotherapy. Patients in the treatment group were additionally applied at Shenque (RN8), exchanging once per every other day, for 14 successive days. Patients in the control group took placebos with the same dose and dosage as the treatment group. The blood cell counts (WBC, NE, and PLT) were detected before chemotherapy, at day 7, 10, and 14. The TCM symptoms integrals, Karnofsky performance score (KPS), liver and kidney functions were observed before chemotherapy, at day 7 and day 14. Adverse skin reactions were observed each day. And the usage of hematopoietic growth factors was recorded. RESULTS: (1) The KPS score at day 7 was more stable in the treatment group than in the control group; the WBC and NE counts in the peripheral blood at day 14 were higher in the treatment group than in the control group; and TCM symptoms integrals at day 14 was lower in the treatment group than in the control group, all with statistical difference (P < 0.05). (2) Compared with the control group, the PLT count was higher in the treatment group than in the control group, the usage of rhG-CSF and antibiotics was less in the treatment group than in the control group, all with no statistical difference (P > 0.05). (3) No obvious adverse reactions such as liver injury, renal injury, or skin allergy were observed. CONCLUSIONS: Adjuvant treatment of GEGC could improve carcinoma of the large intestine patients with myelosuppression to some extent. No relevant adverse reactions were found.
Subject(s)
Bone Marrow Diseases/drug therapy , Colorectal Neoplasms/drug therapy , Drugs, Chinese Herbal/therapeutic use , Adjuvants, Immunologic/therapeutic use , Adult , Aged , Bone Marrow Diseases/chemically induced , Female , Humans , Male , Middle AgedABSTRACT
In the spectral investigation of crude oil samples, it has been found that the synchronous fluorescence spectra (SFS) of the crude oil sample varied with the concentration in both the intensity and the location of peaks. Considering the information about both the changes in SFS, a new method for the concentration determination of crude oil sample using three-dimensional synchronous fluorescence was developed and introduced in the present paper. A number of samples have been investigated to verify the feasibility of the method. The concentration of each sample has been determined with a deviation under 3% in the concentration range from 10(-4) to 1.0 g x L(-1). All the results suggest that the newly developed method may become an useful means in petroleum logging.
ABSTRACT
Fluorescence techniques based on emission spectrum, synchronous fluorescence spectrum (SFS), or three-dimensional (3D) fluorescence spectrum, have been widely used in medical, biological and chemical analyses. In the present paper, 25 crude oil samples from 15 different borefields in the concentration range from 10(-4) g x L(-1) to 10 g x L(-1) have been investigated with different spectral approaches. It was shown that, compared with conventional emission spectrum based technique used in oil logging, the 3D fluorescence technique can provide much more information in the analysis of crude oil samples but at the price of time consuming. While the SFS spectrum of a crude oil sample, taken under the emission and excitation wavelength synchronous scan with deltalambda=40 nm, can represent the main characteristic of the 3D spectrum provided, with even better spectral qualities. All the results suggest that SFS technique is a more suitable approach in crude oil sample analysis than the other two, and has a great potential to be developed as a new quantitative analysis method in petroleum logging.
